Regional immune mechanisms enhance efficacy of an autologous cellular cancer vaccine with intraperitoneal administration

Widespread peritoneal dissemination is common in patients with gynecologic or gastrointestinal cancers. Accumulating evidence of a central role for regional immunity in cancer control indicates that intraperitoneal immunotherapy may have treatment advantages. This study delineates immune mechanisms...

Full description

Saved in:
Bibliographic Details
Main Authors: Ben Marwedel, Lorél Y. Medina, Henning De May, Joshua E. Adogla, Ellie Kennedy, Erica Flores, Eunju Lim, Sarah Adams, Eric Bartee, Rita E. Serda
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:OncoImmunology
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2024.2421029
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846142254702395392
author Ben Marwedel
Lorél Y. Medina
Henning De May
Joshua E. Adogla
Ellie Kennedy
Erica Flores
Eunju Lim
Sarah Adams
Eric Bartee
Rita E. Serda
author_facet Ben Marwedel
Lorél Y. Medina
Henning De May
Joshua E. Adogla
Ellie Kennedy
Erica Flores
Eunju Lim
Sarah Adams
Eric Bartee
Rita E. Serda
author_sort Ben Marwedel
collection DOAJ
description Widespread peritoneal dissemination is common in patients with gynecologic or gastrointestinal cancers. Accumulating evidence of a central role for regional immunity in cancer control indicates that intraperitoneal immunotherapy may have treatment advantages. This study delineates immune mechanisms engaged by intraperitoneal delivery of a cell-based vaccine comprised of silicified ovarian cancer cells associated with enhanced survival. Vaccine trafficking from the site of injection to milky spots and other fat-associated lymphoid clusters was studied in syngeneic cancer models using bioluminescent and fluorescent imaging, microscopy, and flow cytometry. Spectral flow cytometry was used to phenotype peritoneal immune cell populations, while bioluminescent imaging of cancer was used to study myeloid and T cell dependency, systemic immunity, and vaccine efficacy in models of disseminated high-grade serous ovarian and DNA mismatch-repair proficient microsatellite-stable colorectal cancer. Following intraperitoneal vaccination of mice with ovarian cancer, vaccine cells were rapidly internalized by myeloid cells, with subsequent trafficking to fat-associated lymphoid clusters. Tumor clearance was confirmed to be T cell-mediated, leading to the establishment of local and systemic immunity. Combination immune checkpoint inhibitor and vaccine therapy in mice with advanced disease, characterized by an established suppressive tumor microenvironment, increased the number of mice with non-detectable tumors, however, change in tumor burden compared to vaccine monotherapy was not significant. Vaccination also resulted in tumor clearance in mouse models of metastatic colorectal cancer. This study demonstrates that intraperitoneal vaccine delivery has the potential to enhance vaccine efficacy by activating resident immune cells with the subsequent establishment of protective systemic anti-tumor immunity.
format Article
id doaj-art-23fce03b37b84fb5b0d93b026ac043a8
institution Kabale University
issn 2162-402X
language English
publishDate 2024-12-01
publisher Taylor & Francis Group
record_format Article
series OncoImmunology
spelling doaj-art-23fce03b37b84fb5b0d93b026ac043a82024-12-03T13:49:34ZengTaylor & Francis GroupOncoImmunology2162-402X2024-12-0113110.1080/2162402X.2024.2421029Regional immune mechanisms enhance efficacy of an autologous cellular cancer vaccine with intraperitoneal administrationBen Marwedel0Lorél Y. Medina1Henning De May2Joshua E. Adogla3Ellie Kennedy4Erica Flores5Eunju Lim6Sarah Adams7Eric Bartee8Rita E. Serda9Internal Medicine, University of New Mexico Health Science Center, Albuquerque, NM, USAInternal Medicine, University of New Mexico Health Science Center, Albuquerque, NM, USADepartment of Obstetrics & Gynecology, University of New Mexico Health Science Center, Albuquerque, NM, USAInternal Medicine, University of New Mexico Health Science Center, Albuquerque, NM, USAInternal Medicine, University of New Mexico Health Science Center, Albuquerque, NM, USAInternal Medicine, University of New Mexico Health Science Center, Albuquerque, NM, USAInternal Medicine, University of New Mexico Health Science Center, Albuquerque, NM, USADepartment of Obstetrics & Gynecology, University of New Mexico Health Science Center, Albuquerque, NM, USAInternal Medicine, University of New Mexico Health Science Center, Albuquerque, NM, USAInternal Medicine, University of New Mexico Health Science Center, Albuquerque, NM, USAWidespread peritoneal dissemination is common in patients with gynecologic or gastrointestinal cancers. Accumulating evidence of a central role for regional immunity in cancer control indicates that intraperitoneal immunotherapy may have treatment advantages. This study delineates immune mechanisms engaged by intraperitoneal delivery of a cell-based vaccine comprised of silicified ovarian cancer cells associated with enhanced survival. Vaccine trafficking from the site of injection to milky spots and other fat-associated lymphoid clusters was studied in syngeneic cancer models using bioluminescent and fluorescent imaging, microscopy, and flow cytometry. Spectral flow cytometry was used to phenotype peritoneal immune cell populations, while bioluminescent imaging of cancer was used to study myeloid and T cell dependency, systemic immunity, and vaccine efficacy in models of disseminated high-grade serous ovarian and DNA mismatch-repair proficient microsatellite-stable colorectal cancer. Following intraperitoneal vaccination of mice with ovarian cancer, vaccine cells were rapidly internalized by myeloid cells, with subsequent trafficking to fat-associated lymphoid clusters. Tumor clearance was confirmed to be T cell-mediated, leading to the establishment of local and systemic immunity. Combination immune checkpoint inhibitor and vaccine therapy in mice with advanced disease, characterized by an established suppressive tumor microenvironment, increased the number of mice with non-detectable tumors, however, change in tumor burden compared to vaccine monotherapy was not significant. Vaccination also resulted in tumor clearance in mouse models of metastatic colorectal cancer. This study demonstrates that intraperitoneal vaccine delivery has the potential to enhance vaccine efficacy by activating resident immune cells with the subsequent establishment of protective systemic anti-tumor immunity.https://www.tandfonline.com/doi/10.1080/2162402X.2024.2421029Cell silicificationfat-associated lymphoid clustersmilky spotsToll-like receptor agonistsvaccine
spellingShingle Ben Marwedel
Lorél Y. Medina
Henning De May
Joshua E. Adogla
Ellie Kennedy
Erica Flores
Eunju Lim
Sarah Adams
Eric Bartee
Rita E. Serda
Regional immune mechanisms enhance efficacy of an autologous cellular cancer vaccine with intraperitoneal administration
OncoImmunology
Cell silicification
fat-associated lymphoid clusters
milky spots
Toll-like receptor agonists
vaccine
title Regional immune mechanisms enhance efficacy of an autologous cellular cancer vaccine with intraperitoneal administration
title_full Regional immune mechanisms enhance efficacy of an autologous cellular cancer vaccine with intraperitoneal administration
title_fullStr Regional immune mechanisms enhance efficacy of an autologous cellular cancer vaccine with intraperitoneal administration
title_full_unstemmed Regional immune mechanisms enhance efficacy of an autologous cellular cancer vaccine with intraperitoneal administration
title_short Regional immune mechanisms enhance efficacy of an autologous cellular cancer vaccine with intraperitoneal administration
title_sort regional immune mechanisms enhance efficacy of an autologous cellular cancer vaccine with intraperitoneal administration
topic Cell silicification
fat-associated lymphoid clusters
milky spots
Toll-like receptor agonists
vaccine
url https://www.tandfonline.com/doi/10.1080/2162402X.2024.2421029
work_keys_str_mv AT benmarwedel regionalimmunemechanismsenhanceefficacyofanautologouscellularcancervaccinewithintraperitonealadministration
AT lorelymedina regionalimmunemechanismsenhanceefficacyofanautologouscellularcancervaccinewithintraperitonealadministration
AT henningdemay regionalimmunemechanismsenhanceefficacyofanautologouscellularcancervaccinewithintraperitonealadministration
AT joshuaeadogla regionalimmunemechanismsenhanceefficacyofanautologouscellularcancervaccinewithintraperitonealadministration
AT elliekennedy regionalimmunemechanismsenhanceefficacyofanautologouscellularcancervaccinewithintraperitonealadministration
AT ericaflores regionalimmunemechanismsenhanceefficacyofanautologouscellularcancervaccinewithintraperitonealadministration
AT eunjulim regionalimmunemechanismsenhanceefficacyofanautologouscellularcancervaccinewithintraperitonealadministration
AT sarahadams regionalimmunemechanismsenhanceefficacyofanautologouscellularcancervaccinewithintraperitonealadministration
AT ericbartee regionalimmunemechanismsenhanceefficacyofanautologouscellularcancervaccinewithintraperitonealadministration
AT ritaeserda regionalimmunemechanismsenhanceefficacyofanautologouscellularcancervaccinewithintraperitonealadministration